Sun Pharma Advanced Research Company valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3.75×———
4.44×———
3.11×———
Enterprise multiples
3.40×———
4.02×———
4.04×———
Yield
26.7%———
−4.4%———
Reference — adjusted share basis
₹182.98———
₹48.82₹47.94−₹10.56−₹11.93
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SPARC₹182.98

Sun Pharma Advanced Research Company Ltd.

· Pharma & Health
₹ CrorePeersSTARSHILPAMEDSUPRIYATHYROCARERUBICONVIYASHYATHARTHPARKHOSPSMcap ₹5,938 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————3.75
P/B————4.44
P/Sales————3.11
Enterprise Multiples
EV/Sales————3.40
EV/EBITDA————4.02
EV/EBIT————4.04
Yield
Earnings Yield %————26.68
FCF Yield %————-4.42
Reference — adjusted share basis
Price (FY-end close, adj.)————182.98
EPS (adj.)—-11.93-10.5647.9448.82
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.